Literature DB >> 15277629

Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity.

K Kanai1, S Hirose, H Oguni, G Fukuma, Y Shirasaka, T Miyajima, K Wada, H Iwasa, S Yasumoto, M Matsuo, M Ito, A Mitsudome, S Kaneko.   

Abstract

BACKGROUND AND METHODS: Many missense mutations in the voltage-gated sodium channel subunit gene SCN1A were identified in patients with generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy (SMEI), although GEFS+ is distinct from SMEI in terms of clinical symptoms, severity, prognosis, and responses to antiepileptic drugs. The authors analyzed the localization of missense mutations in SCN1A identified in patients with GEFS+ and SMEI to clarify the phenotype-genotype relationships.
RESULTS: Mutations in SMEI occurred more frequently in the "pore" regions of SCN1A than did those in GEFS+. These SMEI mutations in the "pore" regions were more strongly associated than mutations in other regions with the presence of ataxia and tendency to early onset of disease. The possibility of participation of ion selectivity dysfunction of the channel in the pathogenesis of SMEI was suggested by a mutation in the pore region (R946C) identified in a SMEI patient.
CONCLUSIONS: There was a significant phenotype-genotype relationship in generalized epilepsy with febrile seizures plus and severe myoclonic epilepsy of infancy with SCN1A missense mutations. More severe sodium channel dysfunctions including abnormal ion selectivity that are caused by mutations in the pore regions may be involved in the pathogenesis of SMEI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277629     DOI: 10.1212/01.wnl.0000129829.31179.5b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Severe Myoclonic Epilepsy in Infancy - Adult Phenotype with Bradykinesia, Hypomimia, and Perseverative Behavior: Report of Five Cases.

Authors:  P Martin; B Rautenstrauβ; A Abicht; J Fahrbach; S Koster
Journal:  Mol Syndromol       Date:  2011-03-26

2.  When should clinicians order genetic testing for Dravet syndrome?

Authors:  Jamie K Fountain-Capal; Katherine D Holland; Donald L Gilbert; Barbara E Hallinan
Journal:  Pediatr Neurol       Date:  2011-11       Impact factor: 3.372

Review 3.  Genetics of drug resistance in epilepsy.

Authors:  Sanjay M Sisodiya
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

4.  A plethora of SCN1A mutations: what can they tell us?

Authors:  Robyn Wallace
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

5.  Channeling into the epilepsies.

Authors:  Tracey D Graves; Michael G Hanna
Journal:  Epilepsy Curr       Date:  2008 Mar-Apr       Impact factor: 7.500

6.  Vaccines, encephalopathies, and mutations.

Authors:  Anne T Berg
Journal:  Epilepsy Curr       Date:  2007 Mar-Apr       Impact factor: 7.500

7.  Interaction of voltage-gated sodium channel Nav1.6 (SCN8A) with microtubule-associated protein Map1b.

Authors:  Janelle E O'Brien; Lisa M Sharkey; Christina N Vallianatos; Chongyang Han; Julie C Blossom; Ting Yu; Stephen G Waxman; Sulayman D Dib-Hajj; Miriam H Meisler
Journal:  J Biol Chem       Date:  2012-04-03       Impact factor: 5.157

8.  SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.

Authors:  Huihui Sun; Yuehua Zhang; Jianmin Liang; Xiaoyan Liu; Xiuwei Ma; Husheng Wu; Keming Xu; Jiong Qin; Yu Qi; Xiru Wu
Journal:  J Hum Genet       Date:  2008-06-20       Impact factor: 3.172

9.  The genetics of status epilepticus.

Authors:  Paula Elyse Schauwecker
Journal:  Epilepsia       Date:  2009-12       Impact factor: 5.864

10.  A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.

Authors:  Nanda A Singh; Chris Pappas; E Jill Dahle; Lieve R F Claes; Timothy H Pruess; Peter De Jonghe; Joel Thompson; Missy Dixon; Christina Gurnett; Andy Peiffer; H Steve White; Francis Filloux; Mark F Leppert
Journal:  PLoS Genet       Date:  2009-09-18       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.